AbbVie clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-08
What changed in the last 30 days
39 trials changed in the last 30 days: 1 stopped, 7 with notable changes, 31 with minor changes only.
- Minor: Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space · and Without Diabetic Retinopathy Trial status changed: Enrolling by Invitation → Active, Not Recruiting
- Minor: How Multiple Doses of Itraconazole Interacts With Nacresertib in Healthy Adult Participants Trial completed
- Minor: ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics · Obesity Enrollment closed, study ongoing
- Minor: Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA · Moderate to Severe Upper Facial Lines Trial sites expanded: 1 → 21 locations
- Minor: Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body · B-Cell Malignancies Trial arms changed: 4 → 1
- Minor: Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants · Glabellar Lines Enrollment closed, study ongoing
- Minor: LEGACY · Registry of Humira® (Adalimumab) · Moderately to Severely Active Ulcerative Colitis (UC) Trial completed
- Notable: Food Effect Study of ABBV-7828 in Healthy Adults Recruitment opened
- Minor: NAAVIGATE · Surabgene Lomparvovec Administered in the Suprachoroidal Space · Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema Trial sites expanded: 37 → 40 locations
- Notable: AURORA · MEDI0618 Compared to Placebo · Episodic Migraine Primary endpoint(s) modified
- Minor: KEEPsAKE2 · Risankizumab to Placebo · Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) Sponsor refiled this as active, not recruiting (was completed)
- Minor: Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor · Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations Trial sites expanded: 124 → 127 locations
- Minor: ABBV-295 · Obesity or Overweight With Weight-Related Comorbidities Trial sites expanded: 61 → 64 locations
- Minor: Upadacitinib · Alopecia Areata Trial sites expanded: 9 → 13 locations
- Minor: AGN-151607-DP to Assess Adverse Events and Change in Disease Activity · Upper Limb Essential Tremor Trial sites expanded: 3 → 20 locations
- Stopped: Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies · Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Trial terminated
- Notable: Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants Recruitment opened
- Minor: Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec · Neovascular Age-Related Macular Degeneration (nAMD) Trial sites expanded: 133 → 136 locations
- Minor: MIGHTY · How Risankizumab Works in Young · Ulcerative Colitis Trial sites expanded: 68 → 71 locations
- Minor: Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine · Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Trial sites expanded: 70 → 73 locations
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-29 | NCT07904754 Platform Study of Targeted Therapies for Adults With Moderately to Severely Active… | Phase 2 | Not Yet Recruiting |
| 2026-10-27 | NCT07896421 Real-World Study of Mirvetuximab Soravtansine in Adult Participants With… | Recruiting | |
| 2026-10-27 | NCT07896434 A Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young… | Phase 3 | Not Yet Recruiting |
| 2026-10-26 | NCT07895043 A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV)… | Phase 2 | Not Yet Recruiting |
| 2026-10-26 | NCT07895056 A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV)… | Phase 2 | Not Yet Recruiting |
| 2026-10-19 | NCT07880756 Safety and Effectiveness of NOA HYDRATION Injectable Gel for the Improvement of Skin… | Phase 3 | Recruiting |
| 2026-10-13 | NCT07871513 A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and… | Phase 2 | Recruiting |
Active trials by phase
| Phase 1 | 50 | |
| Phase 1/2 | 10 | |
| Phase 2 | 52 | |
| Phase 2/3 | 10 | |
| Phase 3 | 63 | |
| Phase 4 | 4 |
Not charted: 50 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials, top 10 of 51
Leukemia (21) · Lung Cancer (21) · Multiple Myeloma (17) · Non-Small Cell Lung Cancer (NSCLC) (16) · Ovarian Cancer (16) · Crohn's Disease (15) · Migraine (13) · Ulcerative Colitis (13) · Chronic Lymphocytic Leukemia (CLL) (11) · Psoriasis (11)
Get alerts when AbbVie's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.